科兴制药：人干扰素α 1b吸入溶液纳入突破性治疗品种名单

Core Viewpoint - The announcement highlights that the company's subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has developed an inhalation solution of human interferon α 1b, which has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration's Drug Review Center [1] Group 1: Product Development - The inhalation solution is a significant breakthrough in the antiviral field, specifically designed for children [1] - The product is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly compared to injection [1] - The solution is indicated for pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis [1] Group 2: Advantages of the Product - The inhalation method eliminates the pain associated with injections, leading to higher acceptance and safety for pediatric patients [1] - The broad-spectrum antiviral, antitumor, and immune-regulating properties of interferon make it a key component of the body's natural immunity [1]